Key result
Cardiometabolic HFpEF emerges as a distinct, rising endotype driven by obesity and metabolic disease.
Why the study?
Cardiometabolic HFpEF is a dominant endotype with rising prevalence, but success in developing an efficacious therapeutic arsenal has been modest, necessitating relevant animal models to provide mechanistic and clinical insights.
Key points are not available for this paper at this time.
Design
Review
Alerts to rising cardiometabolic HFpEF burden; leaves open endotype-specific therapies pending validation.
Cardiometabolic heart failure with preserved ejection fraction (HFpEF) has emerged as a distinct and dominant endotype of HFpEF. Driven by prevalent comorbidities, its incidence and prevalence are projected to continue to rise amid the current global pandemic of obesity and metabolic disease. Recognizing the characteristic clinical and molecular features of cardiometabolic HFpEF is paramount for developing an efficacious therapeutic arsenal and improving clinical outcomes, challenges in which success to date has been modest. Studying relevant and clinically informative animal models of cardiometabolic HFpEF can afford valuable insights into the molecular underpinnings of this syndrome, allowing the possibility of novel advances with clinical relevance. Here, we outline the clinical and molecular features that define cardiometabolic HFpEF as a distinct endotype. We also discuss the bona fide animal models of cardiometabolic HFpEF currently available, as well as methods for developing new models.
No takes yet. Share an insight, caveat, or question.
Daou et al. (2025) studied this question. Cardiometabolic heart failure with preserved ejection fraction (HFpEF) is a distinct endotype driven by obesity and metabolic disease, with rising incidence due to prevalent comorbidities.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: